ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicCheckpoint immunotherapy: Reshaping the landscape of gastrointestinal cancer treatment - Volume IIView all 10 articles
Neoadjuvant Serplulimab and SOX Chemotherapy for Locally Advanced Gastric Cancer: Pathological Responses and Systemic Immune Signatures from a Phase II Trial
Provisionally accepted
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Neoadjuvant immunotherapy combined with chemotherapy is an emerging strategy for improving outcomes in patients with locally advanced gastric cancer (LAGC). However, clinical evidence regarding the efficacy of serplulimab plus SOX chemotherapy and its immunologic correlates remains limited. Methods In this prospective, single-center, phase II trial, patients with cT3-4N+M0 resectable gastric or gastroesophageal junction adenocarcinoma received three cycles of serplulimab combined with SOX chemotherapy, followed by D2 gastrectomy and adjuvant therapy. The primary endpoints were pathological complete response (pCR) and major pathological response (MPR). Circulating immune markers, including cytokines (e.g., IL-1β, TNF-α) and T-cell subsets (e.g., CD4⁺/Treg ratio), were profiled longitudinally to evaluate immune remodeling during neoadjuvant therapy. The exploratory role of perioperative parenteral nutrition (PN) was also assessed. Results Among the 33 enrolled patients, all underwent surgery and achieved R0 resection. The pCR and MPR rates were 21.21% and 36.36%, respectively. The 12-month event-free survival (EFS) rate was 82.20% (68.99-97.94). Patients achieving MPR exhibited elevated preoperative IL-1β levels, a lower CD4⁺/Treg ratio, and a higher Treg/CD8+ ratio, suggesting that systemic immune activation may predict better pathological response. While PN transiently preserved lymphocytes and reduced inflammation preoperatively, it showed no sustained postoperative immune effect. Conclusion Neoadjuvant serplulimab plus SOX chemotherapy demonstrates promising efficacy in LAGC, with immunologic remodeling potentially serving as a predictor of treatment response. The identification of non-invasive, blood-based immune biomarkers may help guide future patient selection and therapeutic optimization. The ongoing phase III trial (NCT04139135) will validate the efficacy of this perioperative immunochemotherapy strategy in LAGC.
Keywords: gastric cancer, neoadjuvant immunotherapy, serplulimab, SOX chemotherapy, Pathological response, Systemic immunity, Cytokines, T-cell subsets
Received: 10 Sep 2025; Accepted: 19 Dec 2025.
Copyright: © 2025 Zhan, Liu, Cai and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Weilin Sun
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.